News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Delenex Therapeutics Release: New Clinical Data On The Topical Application Of PENTRA®Bodies To Be Presented At The 44th Annual ESDR Meeting



9/2/2014 2:26:50 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Zurich, September 2, 2014 - Delenex Therapeutics AG, a clinical stage biopharmaceutical company primarily developing treatments for dermatologic diseases using its proprietary PENTRA®Bodies, today announced that Prof. Dr. Georg Stingl from the Medical University in Vienna, Austria will present a late-breaking poster on new clinical data of DLX105 at this year’s European Society for Dermatological Research Meeting in Copenhagen, Denmark. DLX105 is an anti-TNF? PENTRA®Body based on Delenex’ proprietary antibody platform that is applied topically to the skin of mild to moderate psoriasis patients.

The poster (LB011) “Topical administration of the single-chain anti-TNF? antibody DLX105 suppresses TNF? and Th17 cytokines in psoriatic skin“ will be presented on Thursday, September 11, 2014, at 6:30 PM in the late-breaking poster area at the Tivoli Congress Center in Copenhagen, Denmark.

Further information can be found on the ESDR 2014 website http://www.esdr2014.org/.

About Delenex Therapeutics AG

Delenex is a privately-held, clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from psoriasis, hidradenitis suppurativa, acne and other, dermatological and non-dermatologic, diseases. Delenex’ proprietary PENTRA®Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body. Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).

For further details please contact:

Jakob Schlapbach, CFO
Delenex Therapeutics AG
Wagistrasse 27
CH-8952 Schlieren
E-mail: jakob.schlapbach@delenex.com
Website: www.delenex.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES